IN8bio ( NASDAQ:INAB – Get Free Report ) posted its earnings results on Thursday. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.10, FiscalAI reports.
IN8bio Stock Performance
NASDAQ INAB traded up $0.10 on Friday, hitting $0.93. 33,376 shares of the stock were exchanged, compared to its average volume of 39,109. The stock has a fifty day moving average price of $1.13 and a two-hundred day moving average price of $1.42. The firm has a market capitalization of $9.14 million, a P/E ratio of -0.92 and a beta of 0.27. IN8bio has a 52-week low of $0.80 and a 52-week high of $2.73.
Get IN8bio alerts:
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of IN8bio in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.
IN8bio Company Profile
( Get Free Report )
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T ce...